Patents by Inventor THOMAS MATTHEW WEBB

THOMAS MATTHEW WEBB has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIGEN BINDING PROTEINS
    Publication number: 20230295295
    Abstract: This application discloses antigen binding proteins that bind Lymphocyte Activation Gene 3 (LAG-3), and more particularly to antigen binding proteins that cause depletion of LAG-3+ activated T cells.
    Type: Application
    Filed: January 19, 2023
    Publication date: September 21, 2023
    Inventors: Paul Andrew HAMBLIN, Alan Peter Lewis, Thomas Matthew Webb
  • ANTIGEN BINDING PROTEINS
    Publication number: 20230242642
    Abstract: Antigen binding proteins that bind Lymphocyte Activation Gene 3 (LAG-3), and more particularly to antigen binding proteins that cause depletion of LAG-3+ activated T cells.
    Type: Application
    Filed: January 11, 2023
    Publication date: August 3, 2023
    Inventors: Paul Andrew HAMBLIN, Alan Peter Lewis, Thomas Matthew Webb
  • ANTIGEN BINDING PROTEINS
    Publication number: 20190382482
    Abstract: This application discloses antigen binding proteins that bind Lymphocyte Activation Gene 3 (LAG-3), and more particularly to antigen binding proteins that cause depletion of LAG-3+ activated T cells.
    Type: Application
    Filed: May 30, 2019
    Publication date: December 19, 2019
    Inventors: Paul Andrew HAMBLIN, Alan Peter Lewis, Thomas Matthew Webb
  • ANTIGEN BINDING PROTEINS
    Publication number: 20190276535
    Abstract: Antigen binding proteins that bind Lymphocyte Activation Gene 3 (LAG-3), and more particularly to antigen binding proteins that cause depletion of LAG-3+ activated T cells.
    Type: Application
    Filed: March 19, 2019
    Publication date: September 12, 2019
    Inventors: Paul Andrew HAMBLIN, Alan Peter Lewis, Thomas Matthew WEBB
  • Antigen binding proteins
    Patent number: 10344088
    Abstract: This application discloses antigen binding proteins that bind Lymphocyte Activation Gene 3 (LAG-3), and more particularly to antigen binding proteins that cause depletion of LAG-3+ activated T cells.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: July 9, 2019
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Paul Andrew Hamblin, Alan Peter Lewis, Thomas Matthew Webb
  • Anti-LAG-3 binding proteins
    Patent number: 10280221
    Abstract: Antigen binding proteins that bind Lymphocyte Activation Gene 3 (LAG-3), and more particularly to antigen binding proteins that cause depletion of LAG-3+ activated T cells.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: May 7, 2019
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Paul Andrew Hamblin, Alan Peter Lewis, Thomas Matthew Webb
  • ANTI-LAG-3 BINDING PROTEINS
    Publication number: 20160017037
    Abstract: Antigen binding proteins that bind Lymphocyte Activation Gene 3 (LAG-3), and more particularly to antigen binding proteins that cause depletion of LAG-3+ activated T cells.
    Type: Application
    Filed: March 13, 2014
    Publication date: January 21, 2016
    Inventors: Paul Andrew HAMBLIN, Alan Peter LEWIS, Thomas Matthew WEBB
  • CD127 binding proteins
    Patent number: 9150653
    Abstract: Antigen binding proteins which bind to human IL-7 receptor (CD127) are provided. The antigen binding proteins are typically antibodies, and are useful in the treatment of diseases or disorders in humans, particularly autoimmune diseases such as multiple sclerosis.
    Type: Grant
    Filed: January 26, 2011
    Date of Patent: October 6, 2015
    Assignee: Glaxo Group Limited
    Inventors: Ian Kirby, Alexander H. Taylor, Thomas Matthew Webb, Yu Xue
  • CD127 binding proteins
    Patent number: 8940303
    Abstract: Antigen binding proteins which bind to human IL-7 receptor (CD127) are provided. The antigen binding proteins are typically antibodies, and are useful in the treatment of diseases or disorders in humans, particularly autoimmune diseases such as multiple sclerosis.
    Type: Grant
    Filed: January 26, 2011
    Date of Patent: January 27, 2015
    Assignee: Glaxo Group Limited
    Inventors: Ian Kirby, Alex H. Taylor, Thomas Matthew Webb, Yu Xue
  • ANTIGEN BINDING PROTEINS
    Publication number: 20140286935
    Abstract: This application discloses antigen binding proteins that bind Lymphocyte Activation Gene 3 (LAG-3), and more particularly to antigen binding proteins that cause depletion of LAG-3+ activated T cells.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 25, 2014
    Applicant: Glaxosmithkline Intellectual Property Development Limited
    Inventors: Paul HAMBLIN, Alan Lewis, Thomas Matthew Webb
  • CD127 BINDING PROTEINS
    Publication number: 20120282254
    Abstract: Antigen binding proteins which bind to human IL-7 receptor (CD127) are provided. The antigen binding proteins are typically antibodies, and are useful in the treatment of diseases or disorders in humans, particularly autoimmune diseases such as multiple sclerosis.
    Type: Application
    Filed: January 26, 2011
    Publication date: November 8, 2012
    Inventors: Ian Kirby, Alexander H. Taylor, Thomas Matthew Webb, Yu Xue
  • CD127 BINDING PROTEINS
    Publication number: 20110200585
    Abstract: Antigen binding proteins which bind to human IL-7 receptor (CD127) are provided. The antigen binding proteins are typically antibodies, and are useful in the treatment of diseases or disorders in humans, particularly autoimmune diseases such as multiple sclerosis.
    Type: Application
    Filed: January 26, 2011
    Publication date: August 18, 2011
    Inventors: IAN KIRBY, ALEX H. TAYLOR, THOMAS MATTHEW WEBB, YU XUE